Abstract:Objective Beraprost was developed as the first oral prostacyclin analog to treat patients with pulmonary arterial hypertension (PAH). Although this drug demonstrates improvements in the patient's exercise capacity and symptoms, it carries a weak recommendation in the PAH evidence-based treatment algorithm due to a lack of durability of effects. However, this therapy remains a major treatment method in Japan due to its availability and inexpensive cost. The purpose of this study was to elucidate whether this dr… Show more
“…Beraprost was approved in Japan as an oral treatment for PAH in 1999 and is widely used there although survival benefits have been hard to demonstrate [11,12]. Although United therapeutics has evaluated various formulations of beraprost since 2000, it has yet to seek US approval for any such formulation.…”
This IP receptor agonist represents the first example of selecting a compound to treat PAH that was designed for delivery via inhalation. It indicates Novartis' desire to establish a broad portfolio of respiratory products.
“…Beraprost was approved in Japan as an oral treatment for PAH in 1999 and is widely used there although survival benefits have been hard to demonstrate [11,12]. Although United therapeutics has evaluated various formulations of beraprost since 2000, it has yet to seek US approval for any such formulation.…”
This IP receptor agonist represents the first example of selecting a compound to treat PAH that was designed for delivery via inhalation. It indicates Novartis' desire to establish a broad portfolio of respiratory products.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.